Premiere Date: November 20, 2016
Expiration Date: May 20, 2018
This activity offers CE credits for:
1. Physicians (CME)
To understand the role of neurofeedback as an intervention to target symptoms associated with psychiatric disorders.
At the end of this CE activity, participants should be able to:
• Discuss neurofeedback mechanisms of action
• Discuss the importance of using quantitative EEG to assess which patients can benefit from specific neurofeedback protocols
• Describe various neurofeedback protocols and techniques
This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.
CME Credit (Physicians): This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process.
The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Deborah Simkin, MD, has no disclosures to report.
Joel Lubar, MD, has no disclosures to report.
James Lake, MD (peer/content reviewer), has no disclosures to report.
Applicable Psychiatric Times staff and CME Outfitters staff have no disclosures to report.
UNLABELED USE DISCLOSURE
Faculty of this CME/CE activity may include discussion of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity?
Call us at 877.CME.PROS (877.263.7767)
This article discusses the history of biofeedback, the use of quantitative EEG (QEEG) to develop protocols to target symptoms associated with psychiatric disorders, and the use of more advanced forms of neurofeedback (eg, low-resolution electromagnetic tomography [LORETA]) to target hubs and circuits. The ability to target circuits fits well with the NIH Research Domain Criteria (RDoC) framework to study mental disorders.
Dr. Simkin is Clinical Assistant Professor, Department of Psychiatry, Emory University School of Medicine, Atlanta, GA. Dr. Lubar is Professor Emeritus, Department of Psychology, University of Tennessee, Knoxville, TN; and Affiliate Scientist for the Center of Complex Systems and Brain Sciences, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, FL.
1. Howe RC, Sterman MB. Cortical-subcortical EEG correlates of suppressed motor behavior during sleep and waking in the cat. J EEG Clin Neurophysiol. 1972;32:681-695.
2. Sterman MB, MacDonald LT, Stone RK. Biofeedback training of the sensorimotor electroencephalographic rhythm in man: effects on epilepsy. Epilepsia. 1974;15:395-416.
3. Lubar JF, Shouse MN. EEG and behavioural changes in a hyperkinetic child concurrent with training of the sensorimotor rhythm (SMR): a preliminary report. Biofeedback Self Regul. 1976;3:293-306.
4. Shouse MN, Lubar JF. Operant conditioning of EEG rhythms and Ritalin in the treatment of hyperkinesis. Biofeedback Self Regul. 1979;4:299-311.
5. Lubar JF. Discourse on the development of EEG diagnostics and biofeedback for attention-deficit/hyperactivity disorders. Appl Psychophysiol Biof. 1991;16:201-202.
6. Rockstroh B, Elbert, Birbaumer N, Wolf P, et al. Cortical self-regulation in patients with epilepsies. Epilep Res. 1993;14:63-72.
7. Heinrich H, Gevensleben H, Freisleder FJ, et al. Training of slow cortical potentials in attention-deficit/hyperactivity disorder: evidence for positive behavioral and neurophysiological effects. Biol Psychiatry. 2004;55:772-775.
8. Arns M, de Ridder S, Strehl U, et al. Efficacy of neurofeedback treatment in ADHD: the effects on inattention, impulsivity and hyperactivity: a meta-analysis. Clin EEG Neurosci. 2009;40:180-189.
9. Monastra VJ, Lynn S, Linden M, et al. Electroencephalographic biofeedback in the treatment of attention-deficit/hyperactivity disorder. Appl Psychophysiol Biofeedback. 2005;30:95-113.
10. Arns M, Drinkenburg W, Kenemans JL. The effects of QEEG-informed neurofeedback in ADHD: an open-label pilot study. Appl Psychophysiol Biof. 2012;37:171-180.
11. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2009;19:353-364.
12. Arns M, Heinrich H, Strehl U. Evaluation of neurofeedback in ADHD: the long and winding road. Biol Psychol. 2014;95:108-115.
13. Duric NS, Assmus J, Gundersen DI, Elgen IB. Neurofeedback for the treatment of children and adolescents with ADHD: a randomized and controlled clinical trial using parental reports. BMC Psychiatry. 2012;12:107.
14. Meisel V, Servera M, Garcia-Banda G, et al. Neurofeedback and standard pharmacological intervention in ADHD: a randomized controlled trial with six-month follow-up. Biol Psychol. 2013;94:12-21.
15. Gevensleben H, Holl B, Albrecht B, et al. Neurofeedback training in children with ADHD: 6-month follow-up of a randomised controlled trial. Eur Child Adolesc Psychiatry. 2010;19:715-724.
16. Leins U, Goth G, Hinterberger T, et al. Neurofeedback for children with ADHD: a comparison of SCP and theta/beta protocols. Appl Psychophysiol Biof. 2007;32:73-88.
17. Strehl U, Leins U, Goth G, et al. Self-regulation of slow cortical potentials: a new treatment for children with attention deficit hyperactivity disorder. Pediatrics. 2006;118:1530-1540.
18. Gani C, Birbaumer N, Strehl U. Long term effects after feedback of slow cortical potentials and of theta-beta-amplitudes in children with attention deficit/hyperactivity disorder (ADHD). Int J Bioelectromag. 2009; 10:209-232.
19. Steiner N, Frenette E, Rene K, et al. In-school neurofeedback training for ADHD: sustained improvements from a randomized control trial. Pediatrics. 2014;133:483-492.
20. Kouijzer M, de Moor J, Gerrits B. Long-term effects of neurofeedback treatment in autism. Res ASD. 2009;3:496-501.
21. Kouijzer ME, van Schie HT, de Moor JM, et al. Neurofeedback treatment in autism. Preliminary findings in behavioral, cognitive, and neurophysiological functioning. Res ASD. 2010;4:386-399.
22. Coben R, Arns M, Kouijzer M. Enduring effects of neurofeedback in children. In: Coben R, Evans JR, eds. Neurofeedback and Neuromodulation Techniques and Applications. San Diego, CA: Academic Press; 2010:403-422.
23. Coben R. Four channel multivariate coherence training: rationale and findings. Presented at: ISNR 22nd Annual Conference; October 2015; San Diego, CA.
24. Becerra J, Fernández T, Harmony T, et al. Follow-up study of learning-disabled children treated with neurofeedback or placebo. Clin EEG Neurosci. 2006;37:198-203.
25. Coben R, Wright EK, Decke SL, Morgan T. The impact of coherence neurofeedback on reading delays in learning disabled children: a randomized controlled study. NeuroRegulat. 2015;2:168-178.
26. Simkin D, Thatcher RW, Lubar J. Quantitative EEG and neurofeedback in children and adolescents: anxiety disorders, depressive disorders, comorbid addiction and attention-deficit/hyperactivity disorder, and brain injury. Child Adolesc Psychiatr Clin N Am. 2014;23:427-464.
27. Lancaster JL, Woldorff MG, Parsons LM, et al. Automatic Talairach atlas labels for functional brain mapping. Hum Brain Mapp. 2000;20:120-131.
28. Valdes-Sosa P, Valdes-Sosa M, Carballo J, et al. QEEG in a public health system. Brain Topog. 1992;4:259-266.
29. Thatcher RW. Handbook on Quantitative Electroencephalography and EEG Biofeedback. St Petersburg, FL: Anipublishing; 2012.
30. Pascual-Marqui RD, Michel CM, Lehmann D. Low resolution electromagnetic tomography: a new method for localizing electrical activity in the brain. Int J Psychophysiol. 1994;18:49-65.
31. Pascual-Marqui RD. LORETA: Low Resolution Electromagnetic Tomography Standardized and Exact and Zero-error Forever. http://uzh.ch/keyinst/loreta.htm. Accessed September 20, 2016.
32. Krigbaum G, Wigton NL. When discussing neurofeedback, does modality matter? NeuroReg. 2014;1:48-60.
33. Thatcher RW. Latest developments in live z-score training: symptom check list, phase reset, and LORETA z-score biofeedback. J Neurother. 2013;17:69-87.
34. Wigton NL, Krigbaum G. Attention, executive function, behavior, and electrocortical function significantly improved with 19-channel Z-score neurofeedback in a clinical setting: a pilot study. J Am Atten Disord. March 30, 2015; E-pub ahead of print.
35. Keeser D, Kirsch V, Rauchmann B, et al. The impact of source-localized EEG phase neurofeedback on brain activity: a double blind placebo controlled study using simultaneously EEG-fMRI-preliminary results. Submitted for publication. J Human Brain Mapping; 2016.
36. Bauer H, Pllana A. EEG-based local brain activity feedback training. Front Hum Neurosci. 2014;12:1005.
37. Hammond DC. The need for individualization in neurofeedback: heterogeneity in QEEG patterns associated with diagnoses and symptoms. Appl Psychophysiol Biofeedback. 2010;35:31-36.
38. Biofeedback Certification International Alliance. http://www.bcia.org/i4a/pages/index.cfm?pageid=3431. Accessed September 20, 2016.
39. Larsen S, Sherlin L. Neurofeedback: an emerging technology for treating central nervous system dysregulation. Psychiatr Clin N Am. 2013;36:163-168.
40. Gerin M, Fichtenholtz H, Roy A, et al. Real-time fMRI neurofeedback with war veterans with chronic PTSD: a feasibility study. Front Psychiatry. 2016;7:111.
41. Kluetsch R, Ros T, Theberge J, et al. Plastic modulation of PTSD resting-state networks by EEG neurofeedback. Acta Psychiatr Scand. 2014;130:123-136.
42. Foster D, Thatcher RW. Surface LORETA neurofeedback in the treatment of PTSD and mild traumatic brain injury. In: Thatcher, RW, Lubar J, eds. Z Score Neurofeedback Clinical Applications. New York, NY: Elsevier; 2015:59-92.
43. Arnold LE, Lofthouse N, Hersch S, et al. EEG neurofeedback for ADHD double-blind sham-controlled randomized pilot feasibility study trial. J Atten Disord. 2013;17:410-419.